Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder

Схожие документы

• Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder
  по: Hardy Thomas A, et al.
  Опубликовано: (2008-09-01)
• Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
  по: Stauffer, Virginia L, et al.
  Опубликовано: (2010)
• Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder
  по: Deberdt, Walter, et al.
  Опубликовано: (2008)
• S226. A STUDY COMPARING WEIGHT GAIN FROM ALKS 3831 TO OLANZAPINE IN EARLY-ILLNESS YOUNG ADULTS WITH SCHIZOPHRENIFORM, SCHIZOPHRENIA, OR BIPOLAR I DISORDER
  по: Simmons, Adam, et al.
  Опубликовано: (2018)
• Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis
  по: Stauffer, Virginia L, et al.
  Опубликовано: (2009)